


BioShares Biotechnology Clinical Trials Fund (Fri, Apr 19, 2024)

Sell candidate since Apr 19, 2024

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-1.38**
#/ 30112

Trend: Buy
MV Long: Sell
MV Short: Sell
Pivot: Sell
Volume: Buy
MACD: Sell

Tech commentaries:

The **BioShares Biotechnology Clinical Trials** ETF price fell by **-3.02%** on the last day (Friday, 19th Apr 2024) from **\$25.48** to **\$24.71**. It has now fallen 6 days in a row. During the last trading day the ETF fluctuated **4.15%** from a day low at **\$24.57** to a day high of **\$25.59**. The price has fallen in 7 of the last 10 days and is down by **-9.43%** for this period. Volume has increased on the last day by **2 thousand** shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, **2 thousand** shares were bought and sold for approximately **\$51.30** thousand.

Given the current short-term trend, the ETF is expected to rise **4.75%** during the next 3 months and, with a 90% probability hold a price between **\$25.88** and **\$33.68** at the end of this 3-month period.

There are few to no technical positive signals at the moment. The **BioShares Biotechnology Clinical Trials** ETF holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at **\$26.27** and **\$28.43**. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on **Friday, March 01, 2024**, and so far it has fallen **-21.18%**. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). **BioShares Biotechnology Clinical Trials** gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs". The very low volume increases the risk and reduces the other technical signals issued.

BioShares Biotechnology Clinical Trials finds support from accumulated volume at **\$24.63** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the ETF meets some resistance from accumulated volume at **\$26.58**, **\$27.67** and **\$30.48**.

This ETF has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the ETF moved **\$1.02** between high and low, or **4.15%**. For the last week, the ETF has had daily average volatility of **1.83%**.

The **BioShares Biotechnology Clinical Trials** ETF holds several negative signals and despite the positive trend, we believe **BioShares Biotechnology Clinical Trials** will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this ETF. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this ETF since the last evaluation from a Hold/Accumulate to a Sell candidate.

Risk: **Medium**

Evaluation: **Sell Candidate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.